分子对接研究与HLA相关的特异同步药物反应
Kejun Li1, Volker M Lauschke1,2,3,4,5, Yitian Zhou1,2
1Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Drug metabolism reviews
|January 15, 2025
概括
分子对接揭示了特定的HLA等位基因如何引起不可预测的药物反应. 这种计算方法有助于理解药物-HLA相互作用,有助于更安全的药物开发和个性化医疗.
科学领域:
- 药物基因组学 药物基因组学
- 计算化学计算化学
- 免疫学 免疫学 免疫学
背景情况:
- 异常药物反应 (IDR) 是不可预测的,严重的不良事件,与剂量依赖的副作用不同.
- 诸如严重皮肤不良反应 (SCAR) 和药物诱导的肝损伤 (DILI) 等疾病是危及生命的IDR.
- 某些HLA基因 (例如,HLA-B*57:01,HLA-B*15:02,HLA-B*58:01) 与药物诱导的IDR相关,但结构机制尚不清楚.
研究的目的:
- 审查分子对接的应用,以阐明与HLA相关的IDR机制.
- 提供风险HLA基因的概述,并讨论模拟药物-HLA相互作用的分子对接工具的实用性和局限性.
主要方法:
- 用分子对接模拟来分析药物-HLA结合口袋并确定关键结合残留物.
- 案例研究检查了药物与特定的HLA等位基因的结合,包括阿巴卡维尔/流西林与HLA-B*57:01,卡巴马泽平与HLA-B*15:02,以及氨醇与HLA-B*58:01.
- 研究了分子对接的潜力,以选针对各种HLA变异的未知IDR责任的药物.
主要成果:
- 对接分析提供了对药物和HLA等位基因之间的特定相互作用的见解,解释了某些不良事件的基础.
- 这项研究表明,分子对接如何能够使药物-HLA特异性产生差异.
- 分子对接对于预测新药候选药物的潜在IDR是有用的.
结论:
- 分子对接是研究药物-HLA相互作用和理解IDRs背后的机制的宝贵工具.
- 这种方法对预防性HLA类型和开发更安全的药物有重大影响.
- 进一步开发和应用分子对接可以提高药物安全性和个性化医学策略.
相关概念视频
Allergic Drug Reactions
807
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
807
Antigens Involved in Adaptive Immunity
449
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
449


